Vietnam’s non-life market saw 14% growth in H1 2022
November 1 2022 by Kristina Shperlik
-
Fidelidade Macau improves ROE on China border reopening, light rail transit project: Fitch
- November 22
The rating agency has affirmed the P&C carri rating at 'A' (strong) with a stable outlook driven by the insurer's strategic importance to its Portuguese parent company.
-
Emerging Asia may benefit from US tariffs as China suffers: Swiss Re’s Haegeli
- November 21
Tariffs, taxes, and a decrease in trade could be a tipping point for the wider industry as there are many uncertainties around future US presidential decisions, said the reinsurer's group chief economist.
-
P&C GWP growth in mature APAC markets to reach 3.2% in 2024: Swiss Re
- November 20
Emerging Asia will remain the main driving force with non-life premiums to grow at a 7.4% CAGR in 2025‒26 as India outperforms all major developing markets.
-
New Zealand central bank warns Quest Insurance over non-compliance
- November 12
Quest has acknowledged and remedied the breaches of its obligations and is in the process of implementing further risk management measure, RBNZ said.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
